The co‐formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta‐analysis of phase III studies in patients with type 2 diabetes

AIMS: To investigate whether the proven benefits of insulin degludec (IDeg) combined with insulin aspart (IAsp), known as IDegAsp, given twice daily, extend across a wide spectrum of patients with diabetes. MATERIALS AND METHODS: This was a post hoc pooled analysis of 5 phase III randomized, 26‐week...

Descripción completa

Detalles Bibliográficos
Autores principales: Haluzík, Martin, Fulcher, Greg, Pieber, Thomas R., Bardtrum, Lars, Tutkunkardas, Deniz, Rodbard, Helena W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033009/
https://www.ncbi.nlm.nih.gov/pubmed/29451706
http://dx.doi.org/10.1111/dom.13261

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033009/
https://www.ncbi.nlm.nih.gov/pubmed/29451706
http://dx.doi.org/10.1111/dom.13261

Ejemplares similares